CD4⁺ and CD8⁺ Regulatory T Cells (Tregs) Are Elevated and Display an Active Phenotype in Patients with Chronic HCV Mono-infection and HIV/HCV Co-infection
Overview
Authors
Affiliations
The aim of this study was to examine regulatory T cells (Tregs) in peripheral blood and liver tissue in patients with chronic hepatitis C virus (HCV) mono-infection and in patients with HIV/HCV co-infection. In a cross-sectional study were included 51 patients with chronic HCV infection, 24 patients with HIV/HCV co-infection and 24 healthy individuals. CD4⁺ and CD8⁺ Tregs were determined using flow cytometry. Fibrosis was examined by transient elastography. Inflammation, fibrosis and Tregs were determined in liver biopsies from 12 patients. Increased frequency of CD4⁺ and CD8⁺ Tregs was found in HIV/HCV co-infected patients [median: 6.4% (IQR: 5.7-6.9) and 1.0% (0.7-1.2), respectively] compared to HCV mono-infected patients [5.6% (4.2-6.3), P = 0.01 and 0.5% (0.3-0.7), P < 0.001, respectively]. Furthermore, HCV mono-infected patients had increased frequencies of Tregs compared with healthy controls (P < 0.05). However, no associations between the frequency of Tregs and fibrosis were found. Furthermore, characterization of CD4⁺ Tregs using CD45RA demonstrated a higher frequency of activated Tregs in both HCV mono-infected and HIV/HCV co-infected patients compared with healthy controls. Finally, number of intrahepatic Tregs was associated with both peripheral CD8⁺ Tregs and intrahepatic inflammation. In conclusion, HCV mono-infected patients and particularly HIV/HCV co-infected patients have increased the frequency of CD4⁺ and CD8⁺ Tregs compared with healthy controls. Furthermore, CD4⁺ Tregs in infected patients displayed an active phenotype. Tregs were not associated with fibrosis, but a positive correlation between intrahepatic Tregs and inflammation was found. Taken together, these results suggest a role for Tregs in the pathogenesis of chronic HCV infection.
Grubczak K, Grzeszczuk A, Groth M, Hryniewicz A, Kretowska-Grunwald A, Flisiak R Viruses. 2021; 13(8).
PMID: 34452314 PMC: 8402834. DOI: 10.3390/v13081448.
Bayik D, Lauko A, Roversi G, Serbinowski E, Acevedo-Moreno L, Lanigan C Sci Rep. 2020; 10(1):18848.
PMID: 33139767 PMC: 7606602. DOI: 10.1038/s41598-020-75881-1.
Lymphocyte Landscape after Chronic (HCV) Cure: The New Normal.
Ghosh A, Romani S, Kottilil S, Poonia B Int J Mol Sci. 2020; 21(20).
PMID: 33050486 PMC: 7589490. DOI: 10.3390/ijms21207473.
Zarini G, Martinez S, Campa A, Sherman K, Tamargo J, Hernandez Boyer J J Womens Health (Larchmt). 2020; 29(9):1176-1183.
PMID: 32004098 PMC: 7520913. DOI: 10.1089/jwh.2019.7954.
Garcia-Broncano P, Medrano L, Berenguer J, Gonzalez-Garcia J, Jimenez-Sousa M, Carrero A Cells. 2018; 7(11).
PMID: 30400258 PMC: 6262386. DOI: 10.3390/cells7110196.